David P Macfarlane
Overview
Explore the profile of David P Macfarlane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Church D, Barker P, Burling K, Shinwari S, Kennedy C, Smith D, et al.
Diabet Med
. 2023 Aug;
40(11):e15194.
PMID: 37562398
Aims: Anti-insulin antibodies in insulin-treated diabetes can derange glycaemia, but are under-recognised. Detection of significant antibodies is complicated by antigenically distinct insulin analogues. We evaluated a pragmatic biochemical approach to...
2.
Fiorello M, Treweeke A, Macfarlane D, Megson I
PLoS One
. 2022 May;
17(5):e0267675.
PMID: 35560114
Hyperglycaemia is known to induce endothelial dysfunction and changes in metabolic function, which could be implicated in diabetes-induced cardiovascular disease. To date, however, little is known about the impact of...
3.
Fiorello M, Treweeke A, Macfarlane D, Megson I
Sci Rep
. 2020 Nov;
10(1):19547.
PMID: 33177612
Cardiovascular disease is the primary driver of morbidity and mortality associated with diabetes. Hyperglycaemia is implicated in driving endothelial dysfunction that might underpin the link between diabetes and cardiovascular disease....
4.
Macfarlane D, Yu N, Leese G
Expert Rev Endocrinol Metab
. 2019 Feb;
6(6):747-749.
PMID: 30780871
No abstract available.
5.
Stimson R, Anderson A, Ramage L, Macfarlane D, de Beaux A, Mole D, et al.
Diabetes Obes Metab
. 2017 Feb;
19(6):883-891.
PMID: 28177189
Background And Aims: The effects of glucocorticoids on fuel metabolism are complex. Acute glucocorticoid excess promotes lipolysis but chronic glucocorticoid excess causes visceral fat accumulation. We hypothesized that interactions between...
6.
Macfarlane D, Yu N, Leese G
Ann Endocrinol (Paris)
. 2015 Apr;
76(2):120-7.
PMID: 25882891
Primary hyperparathyroidism is common, with epidemiological studies suggesting it may effect up to 1% of the population, and up to 3% of post-menopausal females. Many cases are diagnosed incidentally on...
7.
Livingstone D, Barat P, Di Rollo E, Rees G, Weldin B, Rog-Zielinska E, et al.
Diabetes
. 2014 Sep;
64(2):447-58.
PMID: 25239636
5α-Reductase type 1 (5αR1) catalyses A-ring reduction of androgens and glucocorticoids in liver, potentially influencing hepatic manifestations of the metabolic syndrome. Male mice, homozygous for a disrupted 5αR1 allele (5αR1...
8.
Upreti R, Hughes K, Livingstone D, Gray C, Minns F, Macfarlane D, et al.
J Clin Endocrinol Metab
. 2014 May;
99(8):E1397-406.
PMID: 24823464
Context: 5α-Reductase (5αR) types 1 and 2 catalyze the A-ring reduction of steroids, including androgens and glucocorticoids. 5α-R inhibitors lower dihydrotestosterone in benign prostatic hyperplasia; finasteride inhibits 5αR2, and dutasteride...
9.
Macfarlane D, Yu N, Leese G
Lancet Diabetes Endocrinol
. 2014 Mar;
1(4):329-40.
PMID: 24622418
Primary hyperparathyroidism, a disorder in which there is a tendency for hypercalcaemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopausal women. Although parathyroidectomy is indicated for...
10.
Yu N, Macfarlane D, Donnan P, Leese G
Clin Endocrinol (Oxf)
. 2013 Aug;
79(6):899-900.
PMID: 23927588
No abstract available.